HSDD Caregiver and Family Resources: How to Support a Woman With Hypoactive Sexual Desire Disorder

What HSDD Actually Is, and Why the Distinction Matters

HSDD is not simply a low sex drive. It is a persistent or recurrent deficiency in sexual desire that causes the woman significant personal distress, and it cannot be fully explained by another medical condition, a relationship problem alone, or a medication side effect. Those two elements, the deficiency AND the distress, are both required for the DSM-5 diagnosis.

The DSM-5 merged the former categories of HSDD and Female Sexual Arousal Disorder into Female Sexual Interest/Arousal Disorder (FSIAD), but HSDD remains the term used in most clinical trials and by the FDA for drug-approval purposes. Your clinician may use either label; they describe overlapping experiences.

Why She Hasn't "Just Talked Herself Out of It"

HSDD has measurable neurobiological underpinnings. The current model frames female sexual desire as a balance between excitatory dopaminergic/noradrenergic signals and inhibitory serotonergic signals in the brain. Research published in Fertility & Sterility confirms that women with HSDD show altered central nervous system processing of sexual stimuli compared with controls. This is not a choice, a character flaw, or something she can override with the right attitude.

HSDD Across the Life Stages

Understanding which life stage she is in helps you understand what is driving her HSDD and what treatments her clinician is likely to consider.

Reproductive years (roughly ages 18-45). HSDD in this group is often linked to hormonal contraception (particularly combined oral contraceptives, which raise sex-hormone-binding globulin and lower free testosterone), mood disorders, relationship distress, or prior trauma. About 8.9% of premenopausal women in the U.S. Meet criteria for HSDD with associated distress.

Perimenopause (typically ages 45-52, but variable). Fluctuating estrogen and progesterone destabilize mood, sleep, and vaginal tissue, all of which erode desire. The loss of desire may arrive before the last menstrual period and can feel sudden and disorienting. The Study of Women's Health Across the Nation (SWAN) found that the odds of low sexual desire increased significantly during the menopausal transition, with bothersome vaginal dryness playing a compounding role.

Post-menopause. Estrogen decline leads to genitourinary syndrome of menopause (GSM), which makes sex uncomfortable or painful. Pain suppresses desire. Prevalence estimates for distressing low desire in postmenopausal women range from 28% to 34%. This is the group in whom systemic hormone therapy and/or local estrogen therapy most often addresses the underlying physiology before other HSDD-specific treatments are added.

Postpartum. Prolactin suppresses estrogen and libido during breastfeeding. Sleep deprivation, body-image shifts, and perineal healing all compound this. HSDD in the postpartum window is extremely common and often resolves, but it deserves clinical attention if it persists beyond weaning.

How HSDD Is Diagnosed: What the Process Looks Like

The diagnostic process matters for caregivers because misunderstanding it leads to misplaced pressure. HSDD is not diagnosed by a blood test. There is no single hormone level that confirms or rules it out.

The DSDS Screener

The Decreased Sexual Desire Screener (DSDS) is a validated four-question tool used in clinical practice to identify generalized acquired HSDD in premenopausal women. Her provider may use this, the Female Sexual Function Index (FSFI), or a full DSM-5 clinical interview. A score on the FSFI desire subscale below 3.3 has been proposed as a threshold, though clinical judgment always takes precedence.

What Gets Ruled Out First

Before an HSDD diagnosis is finalized, her clinician will look for:

• Thyroid dysfunction (hypothyroidism directly suppresses libido)
• Depression and anxiety, which may be causal rather than secondary
• Medications that suppress desire, most commonly SSRIs, SNRIs, combined hormonal contraceptives, and some antihypertensives
• Relationship or contextual factors that alone account for the distress
• Pain disorders, particularly vulvodynia and provoked vestibulodynia, which can mimic or coexist with HSDD

This ruling-out process takes time. That is why women wait an average of 18 months for a diagnosis, a gap that partner impatience can inadvertently extend by creating additional relational pressure.

FDA-Approved Treatments and What Caregivers Should Know About Them

Two drugs are FDA-approved specifically for HSDD in premenopausal women. Neither is a hormone. Neither works like a sexual stimulant. Both require patience.

Flibanserin (Addyi)

Flibanserin is a daily oral pill that acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, effectively rebalancing the excitatory-inhibitory ratio in the brain's desire circuitry. In the BEGONIA trial, premenopausal women taking flibanserin 100 mg nightly reported statistically significant increases in satisfying sexual events (SSEs) and desire scores compared with placebo over 24 weeks.

What caregivers must know about flibanserin:

• It is taken every night at bedtime, not on-demand before sex.
• The most serious risk is hypotension and syncope, which is substantially increased when combined with alcohol. She must avoid alcohol entirely while taking this drug. This is not a preference; it is an FDA REMS program requirement.
• CNS depressants, including benzodiazepines and some antihistamines, also increase this risk.
• Effects build over weeks. The VIOLET trial found that women needed 4-8 weeks before reporting meaningful improvements in desire. Expecting results after one or two doses creates unfair pressure.
• Common side effects include dizziness, somnolence, nausea, and fatigue, especially in the first two weeks.

Bremelanotide (Vyleesi)

Bremelanotide is a melanocortin receptor agonist given as an on-demand subcutaneous injection in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. In the RECONNECT trials, bremelanotide produced statistically significant improvements in desire and reductions in distress compared with placebo in premenopausal women with HSDD.

What caregivers must know about bremelanotide:

• It is not taken daily. She self-injects before a planned sexual encounter.
• Nausea is the most common side effect, affecting approximately 40% of users in clinical trials. An antiemetic (ondansetron) is often prescribed alongside it.
• Transient blood pressure increases occur in most users; women with uncontrolled hypertension or cardiovascular disease should not use it.
• It should not be used more than once every 24 hours, and no more than approximately eight doses per month, per prescribing guidance.
• Flushing and facial redness are common and temporary.

Off-Label Approaches

Several treatments are used off-label for HSDD, particularly in postmenopausal women or in those who do not respond to the two FDA-approved agents:

• Testosterone therapy. No testosterone product is currently FDA-approved for women in the United States, though The Menopause Society (formerly NAMS) supports its use in postmenopausal women with HSDD based on consistent RCT data, at doses that maintain serum testosterone within the normal premenopausal female range. The Global Consensus Statement on Testosterone published in the Journal of Clinical Endocrinology also supports this position.
• Bupropion. Used off-label in women whose desire loss is linked to antidepressant use. A randomized controlled trial in the Journal of Clinical Psychiatry showed bupropion SR improved desire scores in women with SSRI-induced sexual dysfunction.
• Systemic and local estrogen therapy. Appropriate for perimenopausal or postmenopausal women where GSM and estrogen deficiency are primary drivers.

Pregnancy, Lactation, and Contraception: What Every Caregiver Must Know

This section is mandatory reading if she is pregnant, trying to conceive, or breastfeeding.

Flibanserin in Pregnancy and Lactation

Flibanserin is contraindicated in pregnancy. Animal reproduction studies showed embryofetal toxicity at doses comparable to human therapeutic doses. The FDA label states flibanserin should be discontinued if pregnancy is confirmed. Because HSDD clinical trials excluded pregnant women, there is no meaningful human gestational safety data. Women of reproductive age taking flibanserin should use reliable contraception.

Flibanserin is also currently FDA-approved only for premenopausal women. Its use in breastfeeding has not been studied. Until data exist, breastfeeding while taking flibanserin is not recommended. It is not known whether flibanserin passes into human breast milk.

Bremelanotide in Pregnancy and Lactation

Bremelanotide is contraindicated in pregnancy. The FDA label notes that animal studies at doses below the human recommended dose showed increased post-implantation loss and reduced fetal body weight. As with flibanserin, no human pregnancy data exist. Women using bremelanotide must use effective contraception.

Data on lactation transfer are absent. Use during breastfeeding is not recommended.

The Postpartum Picture

Postpartum women have very limited pharmacologic options for HSDD. Both approved drugs are off the table during breastfeeding. The evidence-based approach in this window is:

1. Address prolactin-mediated desire suppression by discussing breastfeeding plans with her OB or midwife.
2. Treat GSM symptoms with local (vaginal) estrogen, which has minimal systemic absorption and is generally considered compatible with breastfeeding per ACOG guidance.
3. Prioritize couples-based psychotherapy and sex therapy.
4. Revisit pharmacologic options after weaning.

The Caregiver's Role: What Actually Helps and What Makes Things Harder

This is the section you may need most.

What the Evidence Says About Partner Involvement

Couples-based interventions consistently outperform individual therapy for sexual dysfunctions when a partner is present and willing. A Cochrane-reviewed analysis of psychological interventions for female sexual dysfunction found that partner-involved therapy produced larger improvements in desire and sexual satisfaction than individual therapy alone. Her recovery is not a solo project.

What Helps

Acknowledge her distress as real. HSDD diagnosis criteria require that the low desire causes her significant distress. She is not content with the situation. She is suffering. Acknowledging this without attaching your own hurt to it first allows space for her to feel supported rather than blamed.

Go to appointments. Ask her if she would like you present for at least one clinical visit. Many women find it helpful for a partner to hear the diagnosis from a clinician directly. This removes the burden of her having to re-explain the medical reality at home.

Learn the REMS requirements for flibanserin. If she is prescribed flibanserin, you are part of her safe-use plan. The no-alcohol requirement is absolute. Having alcohol available at home, or at social events you attend together, complicates her adherence. This is not about control; it is about hypotension risk that can result in fainting or injury.

Adjust the definition of intimacy. Sex therapy frameworks including Sensate Focus (developed by Masters and Johnson and updated by subsequent researchers) help couples rebuild physical closeness without goal-oriented intercourse. Your willingness to participate in prescribed non-goal exercises is a clinical recommendation, not just a lifestyle suggestion.

Track without pressure. If her clinician asked her to keep a sexual event diary (used in many HSDD trials to measure SSEs), offer to help with the logistics, not the data. Do not review her diary without her invitation.

What Makes Things Harder

Pressure and surveillance are the two most commonly cited partner behaviors that worsen HSDD outcomes in clinical sex therapy practice. Asking "did the medication work yet?" after every week, initiating physical contact with an expectation of sex when she has not signaled interest, and framing her HSDD as a relationship threat all increase her performance anxiety and avoidance. These behaviors are understandable responses to frustration, but they reliably slow her progress.

Dismissal is equally harmful. Telling her she "just needs to relax," that she "used to enjoy it," or that you suspect she is using HSDD as an excuse creates shame and erodes her willingness to discuss the condition with you at all.

Finding Support for Yourself as a Caregiver or Partner

HSDD affects both people in a relationship. Your feelings, including frustration, rejection, self-doubt, and grief for the sexual relationship you had, are valid. They also deserve a separate space from hers.

Resources That Are Actually Useful

• Individual therapy with a sex-positive therapist. The American Association of Sexuality Educators, Counselors and Therapists (AASECT) maintains a therapist directory at aasect.org. Look for someone with CSTS (Certified Sex Therapist Supervisor) or CST credentials.
• Couples sex therapy. Ideally with an AASECT-certified sex therapist. The structured Sensate Focus protocol has the strongest evidence base for couples navigating desire discrepancy.
• The International Society for the Study of Women's Sexual Health (ISSWSH). ISSWSH publishes patient-facing resources and a clinician finder at isswsh.org. Their position statement on HSDD provides the clearest summary of current evidence.
• Her prescribing clinician's patient portal. Most WomanRx treatment plans include asynchronous messaging. If you have a question about her medication safety, you can encourage her to ask through the portal rather than relying on internet searches.

What to Do If She Has Not Yet Been Diagnosed

If you believe she may have HSDD but she has not sought care, the most effective thing you can do is name what you observe without framing it as a problem with her. "I've noticed you seem to be struggling with this, and I read that it's a real medical condition with treatment options. Would you want to talk to someone?" opens a door. Ultimatums close it.

ACOG recommends that clinicians routinely screen for sexual health concerns during well-woman visits, which means she may not have been asked. She can ask her clinician directly, or request a telehealth appointment specifically for sexual health.

Who HSDD Treatment Is Right For, and Who Needs a Different Approach First

Not every woman with low desire has HSDD, and not every woman with HSDD needs pharmacotherapy.

Flibanserin is FDA-approved specifically for premenopausal women with generalized, acquired HSDD who do not have another primary cause. It is not the right first step if she:

• Has uncontrolled depression or anxiety (treat those first)
• Is taking a medication known to suppress desire (discuss switching or dose adjustment with her prescriber)
• Has a relationship dynamic that is the primary driver of her avoidance (psychotherapy first)
• Is perimenopausal or postmenopausal (testosterone therapy or hormone therapy may be more appropriate)

Bremelanotide carries the same premenopausal label indication and the same caveats about ruling out secondary causes.

Postmenopausal women with HSDD are more likely to benefit from testosterone therapy (off-label), systemic or local estrogen, or a combination, before or alongside psychotherapy. The Menopause Society's 2022 Hormone Therapy Position Statement addresses this and notes that sexual function improvement is a recognized benefit of systemic hormone therapy in appropriate candidates.

Women with PCOS may have additional complexity: elevated androgens, insulin resistance, and mood symptoms all intersect with desire. Women with endometriosis often have pain-suppressed desire that requires pain management as the first intervention, not desire-specific pharmacotherapy. These conditions need their own clinical conversations.

Evidence Gaps: What We Still Do Not Know

Women have been historically under-represented in sexual medicine research. The two FDA-approved HSDD drugs were studied almost exclusively in premenopausal, cisgender, partnered women. This matters because:

• Data in women with PCOS, endometriosis, or chronic pelvic pain are sparse.
• Postmenopausal HSDD has no FDA-approved pharmacologic option despite a higher prevalence.
• Long-term safety data beyond 12 months for flibanserin and bremelanotide are limited.
• Non-binary and transgender women were not included in key trials.

When her clinician makes a recommendation that goes beyond the two approved drugs, they are working from extrapolated evidence. That is not negligence; it is standard practice in an under-studied field. Asking "is this based on direct data in women like me, or is it extrapolated?" is a reasonable and encouraged question.